BioWorld

July 14, 2009

Tarceva Survival Data Intensify Lung Cancer Maintenance Battle

It's been barely a week since Eli Lilly and Co.'s chemotherapy drug Alimta (pemetrexed) received the first-ever FDA approval in the maintenance treatment of lung cancer, and already the competition is closing in. (BioWorld Today) Read More

Antiplatelet Space Growing, Plavix Still Strong - for Now

Mixed News on H1N1 Emerges from WHO and Nature Study

NewCo News: Cardioxyl's Nitroxyl Donor Drug Starts Testing in Heart Failure

HHS Piles on Swine Flu Money: $884M More for H1N1 Vaccine

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 28, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 28, 2026

Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s

BioWorld Science

Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...

Daybu readthrough in EU? Zevra’s NPC bid flounders

BioWorld

Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...

Transcripta Bio raises funding to advance neuro pipeline

BioWorld Science

Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...